Ulrike Pupp Peglow
Biographic Data
| ID | 10039949 |
|---|---|
| NAME | Ulrike Pupp Peglow |
| GIVEN NAMES | Ulrike Pupp |
| FAMILY NAME | Peglow |
| SIGNATURE | PEGLOW U P |
| AFFILIATIONS | Innsbruck Medical University |
| VERIFIED | No |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 1 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2025 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria
Background Since summer 2024, passive immunization with nirsevimab (Beyfortus ® ) has been recommended for all infants in Austria to prevent severe respiratory syncytial virus (RSV) infection. Maternal vaccination with RSVpreF (Abrysvo ® ), which provides transplacental protection, became available in autumn 2023. The expected public health benefits of these preventive strategies depend largely on widespread acceptance; however, real-world data f…
No prominent works on this page.
Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria
Background Since summer 2024, passive immunization with nirsevimab (Beyfortus ® ) has been recommended for all infants in Austria to prevent severe respiratory syncytial virus (RSV) infection. Maternal vaccination with RSVpreF (Abrysvo ® ), which provides transplacental protection, became available in autumn 2023. The expected public health benefits of these preventive strategies depend largely on widespread acceptance; however, real-world data f…
COVID-19 Impact on Reproduction (1 works) · Immunization (1 works) · Immunization program (1 works) · Parvovirus B19 Infection Studies (1 works) · Population (1 works) · Public health (1 works) · Respiratory viral infections research (1 works) · Vaccination (1 works) · Vaccine-preventable diseases (1 works)